Market closedNon-fractional
Ocuphire Pharma/OCUP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Ocuphire Pharma
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
Ticker
OCUP
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Farmington Hills, United States
Employees
14
Website
www.ocuphire.com
Ocuphire Pharma Metrics
BasicAdvanced
$53M
Market cap
-
P/E ratio
-$0.50
EPS
0.37
Beta
-
Dividend rate
Price and volume
Market cap
$53M
Beta
0.37
Financial strength
Current ratio
8.959
Quick ratio
8.689
Interest coverage (TTM)
-9.14%
Management effectiveness
Return on assets (TTM)
-15.60%
Return on equity (TTM)
-25.89%
Valuation
Price to revenue (TTM)
2.413
Price to book
1.11
Price to tangible book (TTM)
1.11
Price to free cash flow (TTM)
-14.415
Growth
Revenue change (TTM)
-54.30%
Earnings per share change (TTM)
-156.67%
3-year earnings per share growth (CAGR)
-62.20%
What the Analysts think about Ocuphire Pharma
Analyst Ratings
Majority rating from 4 analysts.
Ocuphire Pharma Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.7M
6.25%
Net income
-$7.1M
51.06%
Profit margin
-417.64%
42.18%
Ocuphire Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.24
$0.25
-$0.21
-$0.29
-
Expected
-$0.23
-$0.22
-$0.05
-$0.13
-$0.24
Surprise
6.19%
-212.61%
300.00%
116.42%
-
Ocuphire Pharma News
AllArticlesVideos
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
GlobeNewsWire·2 weeks ago
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
GlobeNewsWire·2 months ago
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ocuphire Pharma stock?
Ocuphire Pharma (OCUP) has a market cap of $53M as of July 27, 2024.
What is the P/E ratio for Ocuphire Pharma stock?
The price to earnings (P/E) ratio for Ocuphire Pharma (OCUP) stock is 0 as of July 27, 2024.
Does Ocuphire Pharma stock pay dividends?
No, Ocuphire Pharma (OCUP) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Ocuphire Pharma dividend payment date?
Ocuphire Pharma (OCUP) stock does not pay dividends to its shareholders.
What is the beta indicator for Ocuphire Pharma?
Ocuphire Pharma (OCUP) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Ocuphire Pharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.